Back to top

Analyst Blog

Zacks Equity Research

Cobrek Pharma in Perrigo's Bag

MYL PRGO

 ZacksTrade Now

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

The spate of acquisitions in the pharmaceutical industry continues with Perrigo Company (PRGO - Analyst Report) completing the purchase of the privately-held Cobrek Pharmaceuticals, Inc.  for approximately $45 million in cash. The transaction has been inked on a cash free and debt free basis.

We remind investors that Perrigo already owns 18.5% of Cobrek Pharma through a deal signed in 2008. In December 2012, Perrigo inked a definitive agreement to acquire the balance 81.5% stake in the privately-held entity.

Per the terms of the deal, Cobrek Pharma, whose primary source of income are the profit shares on offerings partnered with Perrigo, will forgo payments related to profit shares earned during Perrigo's fiscal second quarter 2013. We note that the company’s fiscal year ends on the last Saturday of June every year.

By acquiring the remaining stake in Cobrek Pharma, Perrigo aims to strengthen its position in the topical foam-based generic prescription pharmaceuticals space. The deal is expected to boost Perrigo’s adjusted earnings in fiscal 2013 by $0.04 per share.

We note that Perrigo also inked a deal with Cobrek Pharma in 2008 for developing the foam dosage versions of generic pharmaceutical offerings. The partnership has worked very well and is responsible for the development of two commercialized foam-based products. The products are the generic versions of Evoclin (clindamycin phosphate) foam 1% and Extina (ketoconazole) foam 2%.

Additionally, the deal has yielded two more foam-based products, which have been cleared by the Food and Drug Administration (FDA) but have not yet been launched. The products, expected to be launched in fiscal 2013, are Luxiq (betamethasone valerate) foam and Olux-E (clobetasol propionate) foam 0.05%.

We note that Perrigo has been quite active on the acquisition front lately. Earlier in 2012, Perrigo acquired the entire assets of privately-held Sergeant's Pet Care Products, Inc. Through this acquisition, Perrigo aimed to diversify its business into the lucrative pet care space.

Currently, we have a long-term Neutral recommendation on Perrigo, an S&P 500 stock. The stock carries a Zacks #3 Rank (Hold) in the short run. S&P 500 companies that currently look better-positioned include Mylan Inc. (MYL - Analyst Report). Mylan carries a Zacks #2 Rank (Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GRP IN DXYN 15.84 +7.90%
BOFI HLDG IN BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%